Literature DB >> 21658337

Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Martin Desrosiers1, Gerald A Evans, Paul K Keith, Erin D Wright, Alan Kaplan, Jacques Bouchard, Anthony Ciavarella, Patrick W Doyle, Amin R Javer, Eric S Leith, Atreyi Mukherji, R Robert Schellenberg, Peter Small, Ian J Witterick.   

Abstract

This document provides health care practitioners with information regarding the management of acute rhinosinusitis (ARS) and chronic rhinosinusitis (CRS) to enable them to better meet the needs of this patient population. These guidelines describe controversies in the management of acute bacterial rhinosinusitis (ABRS) and include recommendations that take into account changes in the bacteriologic landscape. Recent guidelines in ABRS have been released by American and European groups as recently as 2007, but these are either limited in their coverage of the subject of CRS, do not follow an evidence-based strategy, or omit relevant stakeholders in the development of guidelines and do not address the particulars of the Canadian health care environment.Advances in understanding the pathophysiology of CRS, along with the development of appropriate therapeutic strategies, have improved outcomes for patients with CRS. CRS now affects large numbers of patients globally, and primary care practitioners are confronted by this disease on a daily basis. Although initially considered a chronic bacterial infection, CRS is now recognized as having multiple distinct components (eg, infection, inflammation), which have led to changes in therapeutic approaches (eg, increased use of corticosteroids). The role of bacteria in the persistence of chronic infections and the roles of surgical and medical management are evolving. Although evidence is limited, guidance for managing patients with CRS would help practitioners less experienced in this area offer rational care. It is no longer reasonable to manage CRS as a prolonged version of ARS, but, rather, specific therapeutic strategies adapted to pathogenesis must be developed and diffused.Guidelines must take into account all available evidence and incorporate these in an unbiased fashion into management recommendations based on the quality of evidence, therapeutic benefit, and risks incurred. This document is focused on readability rather than completeness yet covers relevant information, offers summaries of areas where considerable evidence exists, and provides recommendations with an assessment of the strength of the evidence base and the degree of endorsement by the multidisciplinary expert group preparing the document.These guidelines have been copublished in both Allergy, Asthma, and Clinical Immunology and the Journal of Otolaryngology-Head and Neck Surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658337

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


  33 in total

1.  The personal financial burden of chronic rhinosinusitis: A Canadian perspective.

Authors:  Jonathan Yip; Allan D Vescan; Ian J Witterick; Eric Monteiro
Journal:  Am J Rhinol Allergy       Date:  2017-07-01       Impact factor: 2.467

Review 2.  Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review.

Authors:  Jennifer L Wentzel; Zachary M Soler; Kristen DeYoung; Shaun A Nguyen; Shivangi Lohia; Rodney J Schlosser
Journal:  Am J Rhinol Allergy       Date:  2013 Nov-Dec       Impact factor: 2.467

Review 3.  Antibiotic efficacy in patients with a moderate probability of acute rhinosinusitis: a systematic review.

Authors:  Jakob M Burgstaller; Johann Steurer; David Holzmann; Gabriel Geiges; Michael B Soyka
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-18       Impact factor: 2.503

4.  Chronic nasal congestion and hyposmia in a 22-year-old woman.

Authors:  Mark Bastianelli; Shaun Kilty
Journal:  CMAJ       Date:  2017-05-08       Impact factor: 8.262

Review 5.  The prevalence of olfactory dysfunction in chronic rhinosinusitis.

Authors:  Preeti Kohli; Akash N Naik; E Emily Harruff; Shaun A Nguyen; Rodney J Schlosser; Zachary M Soler
Journal:  Laryngoscope       Date:  2016-11-22       Impact factor: 3.325

6.  Nasal douches for diseases of the nose and the paranasal sinuses--a comparative in vitro investigation.

Authors:  Janna Campos; Werner Heppt; Rainer Weber
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-28       Impact factor: 2.503

Review 7.  Canadian guidelines for acute bacterial rhinosinusitis: clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

8.  A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study.

Authors:  Charlie Tan; Erin Graves; Hong Lu; Anna Chen; Shudong Li; Kevin L Schwartz; Nick Daneman
Journal:  CMAJ Open       Date:  2017-12-21

9.  Canadian guidelines for chronic rhinosinusitis: Clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2013-12       Impact factor: 3.275

Review 10.  Inflammatory Biomarkers During Bacterial Acute Rhinosinusitis.

Authors:  Timo J Autio; Timo Koskenkorva; Petri Koivunen; Olli-Pekka Alho
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.